NCT02463656 is a clinical trial in Focal Dermal Hypoplasia, sponsored by University of Colorado, Denver.

Who is sponsoring NCT02463656?

NCT02463656 is sponsored by University of Colorado, Denver.

What condition does NCT02463656 study?

NCT02463656 studies Focal Dermal Hypoplasia.

Is NCT02463656 still recruiting?

NCT02463656 is currently completed. Last updated 18 June 2018.

Last reviewed 2018-06-18 · How we verify

NCT02463656

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth Arrest in Focal Dermal Hypoplasia

Completed Last updated 18 June 2018

What this trial tests

trial in Focal Dermal Hypoplasia in 16 participants. Completed in 31 May 2018.

Timeline

15 July 2015

Primary endpoint
30 March 2016

31 May 2018

Quick facts

Lead sponsor	University of Colorado, Denver
Status	Completed
Study type	OBSERVATIONAL
Enrollment	16
Start date	15 July 2015
Primary completion	30 March 2016
Estimated completion	31 May 2018

Conditions studied

Focal Dermal Hypoplasia — all drugs for Focal Dermal Hypoplasia →

Sponsor

University of Colorado, Denver

Who can join

Adults 3 to 18, any sex, with Focal Dermal Hypoplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Focal dermal hypoplasia (FDH) is a rare genetic disorder of ectodermal dysplasia caused by mutation in the Porcupine Homolog (Drosophila) (PORCN) gene which results in skin, hair, limb and eye abnormalities. Short stature and underweight have been noted in the majority of these patients. Since the pituitary gland arises from ectodermal tissue, the investigators suspect that pituitary deficiencies may contribute to poor linear growth. This study will examine the nutritional, gastrointestinal and endocrine mechanisms that may account for linear growth stunting and low weight that is observed in FDH. The investigators will utilize standard clinical tools including a bone age xray, glucagon stimulation test to evaluate growth hormone status, baseline laboratory analysis of hormone and nutritional/gastrointestinal markers, food diaries, symptom diaries, and growth charts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Colorado, Denver trials

Trials by the same sponsor.

NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02463656 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 18 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02463656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing